The importance of the blood-brain barrier (BBB) and neuroinflammation in neurodegenerative conditions is becoming increasingly apparent, yet very little is known about these neurovascular functions in nonmalignant disease chronic pain. Neural tissue pericytes play critical roles in the formation and maintenance of the BBB. Herein, we review the important roles of neural pericytes and address their potential role in chronic pain.
INTRODUCTION
The financial burden of treating chronic nonmalignant pain is ever increasing in our ageing global population. There has been a paucity of new pharmacotherapies for chronic nonmalignant pain despite increased attention from researchers and clinicians in areas such as musculoskeletal and neuropathic pain. Over the last four decades, the number of published research articles focussing on chronic pain has risen exponentially yet the number of new therapeutics to treat chronic pain has not risen in tandem, leaving an over-reliance on the old pharmacological classes: opioids, anticonvulsants, antidepressants and NSAIDs [1] . Identifying new targets is key to driving progress in pharmacotherapy of disease. The importance of the neurovascular unit (NVU) and blood-brain barrier (BBB) in neurodegenerative conditions is becoming increasingly apparent yet the potential role(s) of the NVU and BBB in the development and maintenance of chronic pain is/are significantly under researched and could provide new avenues for the treatment of chronic pain conditions. Pericytes are a key component of vascular barrier function. Herein, we review the critical role pericytes play in the BBB and how pericyte (dys)function may contribute to persistent pain states thereby presenting a novel target in the pharmacotherapy of chronic pain in nonmalignant disease.
PERICYTES IN THE BLOOD-BRAIN BARRIER
The BBB and blood-spinal cord barriers (BSCBs) restrict access of potentially harmful cells, molecules and other agents into the central nervous system (CNS) and maintain an appropriate microenvironment for neuronal homeostasis. The multicellular makeup of the CNS microvasculature is composed of
PERICYTES IN NEUROINFLAMMATION
Neuroinflammation is a common symptom in pathophysiological conditions including systemic inflammation, diabetes, stroke, multiple sclerosis and chronic pain conditions [6, 7] . In neuroinflammatory conditions, the BBB and BSCB are disrupted, facilitating entry of blood-borne molecules and cells into the CNS that affect the neural microenvironment [8] . In preclinical painful neuropathy models, the BBB/BSCB is altered [9,10,11 & ,12,13] . Many blood-derived molecules are neurotoxic and can cause neuronal sensitization (e.g. erythrocytic free iron, fibrinogen, plasminogen and thrombin) therefore extravasation of blood-borne molecules in chronic painful conditions with an neuroinflammatory component may contribute to an increased pain state. Most research into CNS barrier disruption has focussed on endothelial, glial and neuronal signalling yet pericyte function is altered in pathophysiological conditions [14, 15] , and because of their close proximity to endothelial cells and their intimate role in the NVU, they have the potential to directly perturb barrier function and permeability. As such, there is great interest in the mechanisms by which pericytes stimulate inflammatory cytokine release and the consequent effects on the endothelium [16 & ]. Pericytes can release a host of factors involved in inflammation when exposed to proinflammatory substances, such as interleukins, chemokines and adhesion molecules [17, 18] , and have been implicated in the promotion of immune cell transendothelial migration (transmigration) [19, 20] . Pericytes are more sensitive to tumour necrosis factor-alpha (TNFa) stimulation, with an increased expression of inflammatory molecules and a larger migratory response compared to other cells of the NVU [21, 22] . Furthermore, pericytes are able to induce greater microglial inducible nitric oxide synthase and interleukin-1b (IL-1b) expression than astrocytes or endothelial cells [21] and produce more matrix metalloproteinase-9 (MMP-9) in response to thrombin stimulation [23, 24] . Therefore, in addition to directly altering barrier function through inflammatory cytokine release, pericytes are able to activate glial cells which can exacerbate the inflammatory response and alter barrier function further [25] . In painful conditions with a neuroinflammatory component, pericytes could be a key driver of prolonged neuroinflammation and barrier disruption (for review,
. There are numerous immune and growth factors that pericytes express which are also implicated in nociception and pain states (see Table 1 MMP production can contribute to neuroinflammation, activate glial cells and can disrupt barrier integrity by degrading the basement membrane and tight junction proteins, and initiate pericyte migration and leukocyte transmigration [22, 62, 63] . MMPs can also trigger vascular endothelial growth factor-a (VEGF-A) production in endothelial cells, which is a potent permeability inducer [64] and a neuronal sensitizer [13, 54] . Pericytes could be a key source of MMP-9 and VEGF-A in pathological conditions. Their close relationship with endothelial cells allows
KEY POINTS
Neurovascular dysregulation in chronic nonmalignant pain conditions is currently under studied.
Pericytes are key for physiological neurovascular function.
Pericytes are intimately involved in neuroinflammatory processes associated with chronic pain conditions. Neurovascular pericytic dysregulation and barrier disruption are observed in painful preclinical models of disease, and may be contributing factors to chronic pain.
Therefore, further research into pericytic dysregulation may reveal novel therapeutic targets for the treatment of chronic pain.
pericytic MMPs to directly act on endothelial tight junctions leading to pathological barrier disruptions [65] . MMPs have been implicated in neuropathic pain [66, 67] , but pericytes as a possible source have not been investigated.
Laminins are the most abundant noncollagenous protein in the basement membrane and are produced by astrocytes, endothelial cells and pericytes [68] . Mice that lack pericyte-derived laminin exhibit hydrocephalus, increased barrier permeability and reduced tight junction expression [68] . In addition, astrocytic function is altered. This demonstrates that pericytes actively contribute towards a physiological basement membrane, and disruption of pericytic-derived laminin can have significant consequences on barrier viability. Pericytes also contribute to remodelling of the basement membrane and facilitate leukocyte transmigration during acute inflammation [69] , but the mechanisms of this are still unclear.
PERICYTES IN CENTRAL NERVOUS SYSTEM IMMUNE INFILTRATION
The CNS, once thought to be an immune-privileged site, is now understood to be neither passive nor isolated from the peripheral immune system with highly regulated movement of leukocytes in and out of the neuronal parenchyma with glia and neurons regulating leukocyte responses (reviewed by [26 & ]). In addition to barrier disruption, pericytic cytokine secretion may contribute to leukocyte chemoattraction and infiltration into the CNS. Leukocytes target interpericytic gaps to transmigrate through the basement membrane and in inflammatory conditions these gaps are both increased in size and number as pericyte morphology and coverage change, in response to inflammatory cytokines such TNFa and various interleukins [18] . There is evidence of leukocyte transmigration into the CNS in preclinical models of painful neuropathy [70,71 & ,72] and that these cells contribute to pain processing. In the nonmalignant painful disease diabetes mellitus, hyperglycaemia results in oxidative stress and pericyte death in the peripheral nervous system (PNS), reducing endoneurial vessel coverage. Endoneurial vessels become more permeable to inflammatory agents including leukocytes [73] , which possibly promotes inflammationinduced neuronal and Schwann cell apoptosis, contributing to the long-term pain associated with diabetic neuropathy [16 & ].
Pericytic intercellular adhesion molecule-1 (ICAM-1) is required for venular leukocyte migration within the basement membrane and finding gaps in the pericytic layer [74 & ]. Work from our laboratory has discovered peripheral inflammatory arthritis drives a CNS glio-vascular response with increased GFAP þ astrocytic end-feet and microvascular ICAM-1 expression in the spinal cord of a preclinical model of inflammatory arthritis [75] . Figure 1 displays an example of the observed ICAM-1 þ microvascular immunofluorescence detected in the dorsal horn of an arthritic mouse which indicates the source of the ICAM-1 immunoreactivity is pericytic. This novel finding opens up many questions, for example are these 'reactive pericytes' promoting the transmigration of immune cells into the cord in response to the peripheral inflammatory reaction? Is the BSCB permeability increase in this model of peripheral inflammatory arthritis [72, 76] due to a pericytic reaction to nociceptive input from the inflamed joint? Our laboratory is attempting to answer these questions.
In-vitro pericyte secretion
Although hyperglycaemic pericyte death and ensuing microvascular dysfunction in the PNS may be a pain-generating mechanism in diabetes mellitus, the cause of pericyte-related pain in inflammatory CCL, C-C-motif ligand; CXCL C-X-C, motif ligand; G-CSF, granulocyte colony stimulating factor; GM-CSF, granulocyte-macrophage colony stimulating factor; ICAM-1, intercellular adhesion molecule-1; IFNg, interferon-g; IL, interleukin; iNOS, inducible nitric oxide synthase; MMP, matrix metalloproteinase; NOX-4, NADPH oxidase-4; PDGF, platelet-derived growth factor; TNFa, tumour necrosis factor-alpha; VCAM-1, vascular adhesion molecule-1; VEGF-A, vascular endothelial growth factor-a.
diseases may be more complex because of the convoluted nature of the cytokine profile secreted by endothelia in inflammatory environments [77 && ]. Because of the intricate interactions between tissues and these cytokines, identifying the molecules within these cascades in vivo is difficult to probe, thus novel methods need to be developed to investigate the inflammatory profile. One such method is a dynamic in-vitro 3D BBB model that subjects cocultures to haemodynamic forces and was designed as an alternative to existing static transwell models. Endothelial cells line an artificial lumen and are cocultured with pericytes or astrocytes embedded in the surrounding collagen matrix [77 && ]. The authors stimulate the cocultures with TNFa to measure the release of five proinflammatory molecules: granulocyte-colony stimulating factor (G-CSF); IL-6; IL-8; IL-17 and granulocytemacrophage CSF [77 && ]. Endothelial cells cultured in the presence of pericytes have an increase in both basal and TNFa-induced secretion of these cytokines, most notably IL-6 and IL-8, highlighting the ability of pericytes to enhance the neuroinflammation. In addition, basal G-CSF, a neuroprotectant [17] , was detected when endothelial cells and pericytes were cultured together but not detected when endothelial cells were cultured alone [16 & ]. This demonstrates the ability of pericytes to stimulate the production of a proneuronal factor which would be lost in pathological conditions associated with pericyte loss.
In chronic inflammation, IL-6, IL-8 and TNFa are correlated with worsening prognoses and more severe levels of diseases: increased levels of IL-6 have been linked to a series of severe polyneuropathies in addition to a number of painful diseases such as osteoarthritis [78 & ,79,80 & ,81]. IL-8 has recently been found to be elevated in the cerebrospinal fluid of chronic pain state patients compared to controls and found to increase over time, correlating with sustained chronic pain [82] . TNFa is increased in the CNS, joints and serum of patients with rheumatoid arthritis and other painful conditions [83] [84] [85] . The pericytic secretion of nociceptive molecules induced by TNFa and other inflammatory mediators provides an additional mechanism by which pericytes may contribute to increased pain state, in addition to regulation of BBB and immune infiltration.
TARGETING PERICYTES TO PROMOTE DELIVERY OF ANALGESICS
The selective BBB is a significant impediment for the delivery of therapeutics targeting CNS sensitization and pain [86, 87] . A reduction in pericyte coverage and tight junctions results in a more permeable BBB and despite the potential for increased noxious cytokine and cell infiltration into the CNS, this increased permeability could provide an opportunity for therapeutics to penetrate the BBB and reach their targets [88] . However, although tight junctions such as ZO-1 and claudins represent a physical component of the BBB, it is the vast arsenal of efflux pumps that appear to present the biggest challenge to analgesic CNS therapy, as common opioids such as morphine operate transcellularly independent of paracellular barrier properties [89] . The efflux pump p-glycoprotein is a key mediator in analgesic removal at the barrier. In a l-carrageenan model of inflammatory pain, in which CNS tight junction proteins such as occludin are decreased, treatment with morphine and the NSAID diclofenac, a common combination to alter barrier permeability, was in fact found to upregulate p-glycoprotein expression in rats and lower morphine delivery to the CNS. Thus, despite changes in permeability, the delivery of analgesic therapy to the CNS can be governed by other factors, including upregulation of efflux transporters highly specific to drug substrates and drugdrug interactions [89] . Nevertheless, targeting pericytes to increase barrier permeability may improve the delivery of some analgesics into the CNS. In addition, p-glycoprotein is expressed by pericytes [90] , yet the role of pericytes in analgesic efflux transporter activity is unknown and certainly worth pursuing.
PERICYTE DIFFERENTIATION INTO A MICROGLIA-LIKE PHENOTYPE
Pericytes can behave like mesenchymal stem cells being able to replace specialized cells such as adipocytes [91] , myocytes [92] , myofibroblasts [93] and odontoblasts [94] in repair processes. In response to FIGURE 2. Summary diagram of the roles pericytes play in CNS vascular biology that could contribute to neuronal sensitization and pain when dysregulated. High pericyte coverage induces high tight junction protein expression to maintain low vessel permeability. A loss in pericyte coverage associated with pathological diseases results in decreased tight junction protein expression, consequent increased permeability and loss of vessel integrity. Extravasation of serum pronociceptive molecules, and pronociceptive and proinflammatory immune cell transmigration are likely to lead to neuronal sensitization and an increased pain state. Pericytes are able to migrate into neuronal parenchyma and differentiate into a microglia-like phenotype, this mechanism may also contribute to an increased pain state. A, astrocyte; AM, adhesion molecule; BM, basement membrane; EC, endothelial cell; L, leukocyte; M, microglia; P, pericyte; RM, reactive microglia.
CNS injury, pericytes can migrate from the microvasculature into the neural parenchyma [95] and differentiate into a microglia-like phenotype [96] [97] [98] , which may be a mechanism that contributes to increased pain. However, it is not known if pericytic migration and differentiation occurs in vascular disrupted painful diseases. If so, this may present a novel mechanism to target in microglial-associated neuroinflammation and neuronal sensitization known to underpin some chronic pain states, in preclinical models and humans [ [4, 104] and reduced pericyte coverage correlates with increased permeability [5] , but the specific mechanisms of pericytic function and neural barrier disruption are not known in chronic pain conditions that are associated with barrier disruption. There has been a small number of studies researching BSCB permeability in painful conditions such as nerve injury [103] and peripheral inflammation [105] , demonstrating increased permeability and disrupted endothelial and barrier functioning; however, pericytic involvement has been largely overlooked. Figure 2 summarizes the key aspects of pericyte biology covered in this review that could lead to pain-generating mechanisms.
CONCLUSION
Because of the intimate relationship between pericytes and barrier health, pericytic dysfunction is likely to be present in painful diseases that have associated neural tissue barrier disruption. Further research into pericyte biology in pain both in preclinical pain models and human studies may unearth pain-generating pericytic mechanisms, which would present novel therapeutic target(s) for the treatment of chronic pain. and Biological Scientific Research Council -Doctoral Training Partnership programme with the University of Nottingham.
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